Cargando…

Enfortumab Vedotin-Induced Toxic Epidermal Necrolysis: A Rare Fatal Adverse Reaction

Detalles Bibliográficos
Autores principales:	Bansal, Aditi, Singh, Jagdeep, Kaur, Sukhjot, Kaur, Navneet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Concise Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809157/ https://www.ncbi.nlm.nih.gov/pubmed/35198485 http://dx.doi.org/10.4103/idoj.idoj_178_21

Ejemplares similares

A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysis
por: Francis, Andrea, et al.
Publicado: (2020)

Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma
por: Mimura, Yuji, et al.
Publicado: (2022)

Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction
por: Viscuse, Paul V., et al.
Publicado: (2021)

Toxic Epidermal Necrolysis Due to Concomitant Use of Lamotrigine and Valproic Acid
por: Kaur, Sukhjot, et al.
Publicado: (2013)

Toxic Epidermal Necrolysis-Like Lesions as Cutaneous Manifestation of Acute Methotrexate Toxicity
por: Singh, Raju, et al.
Publicado: (2020)

Enfortumab Vedotin in urothelial cancer
por: Alt, Marie, et al.
Publicado: (2020)

Drug extravasation with Enfortumab vedotin
por: Grant, Christopher Ryan, et al.
Publicado: (2023)

Flexural Exanthema From Enfortumab Vedotin
por: Keerty, Dinesh, et al.
Publicado: (2020)

Cutaneous reactions with enfortumab vedotin: A case series and review of the literature
por: Dobry, Allison S., et al.
Publicado: (2021)

Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
por: Hanna, Kirollos S.
Publicado: (2020)

Toxic Epidermal Necrolysis induced by rarely implicated drugs
por: Rajagopalan, Sujit, et al.
Publicado: (2012)

THU354 Enfortumab Vedotin Induced Refractory Hyperglycemia
por: Hussein, Marwah, et al.
Publicado: (2023)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Characterization of cutaneous adverse events to enfortumab vedotin: A retrospective case-control study
por: Shahin, Ahmad, et al.
Publicado: (2022)

Fatal case of cephalexin-induced toxic epidermal necrolysis
por: Hafermann, Matthew J, et al.
Publicado: (2014)

Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma
por: Enescu, Christina D., et al.
Publicado: (2022)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
por: Moussa, Mohamad, et al.
Publicado: (2021)

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin
por: Homma, Takamasa, et al.
Publicado: (2023)

Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
por: Fahey, Catherine C., et al.
Publicado: (2023)

Pembrolizumab-Induced Lichen Planus: A Rare Immune-Related Adverse Side Effect
por: Bansal, Aditi, et al.
Publicado: (2023)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
por: Kawahara, Takashi, et al.
Publicado: (2023)

Toxic Epidermal Necrolysis
por: Khalifian, Saami, et al.
Publicado: (2014)

Toxic epidermal necrolysis
por: Hoetzenecker, Wolfram, et al.
Publicado: (2016)

Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
por: Thibodeau, Alexa, et al.
Publicado: (2021)

Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
por: Wu, Qiuji, et al.
Publicado: (2022)

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
por: Shafique, Muhammad Ashir, et al.
Publicado: (2023)

Nivolumab-Induced Toxic Epidermal Necrolysis: Rare but Fatal Complication of Immune Checkpoint Inhibitor Therapy
por: Kim, Michael C, et al.
Publicado: (2021)

A fatal case of cutaneous adverse drug-induced toxic epidermal necrolysis associated with severe rhabdomyolysis
por: Noordally, Sheik Oaleed, et al.
Publicado: (2012)

Toxic Epidermal Necrolysis Caused by Allopurinol: A Serious but Still Underestimated Adverse Reaction
por: Hoyer, Daniel, et al.
Publicado: (2021)

Etoricoxib-induced toxic epidermal necrolysis: A fatal case report
por: Roy, Sukalyan Saha, et al.
Publicado: (2018)

Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System
por: Yang, Hui, et al.
Publicado: (2022)

Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context
por: Hoffman-Censits, Jean, et al.
Publicado: (2022)

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
por: Vulsteke, Christof, et al.
Publicado: (2023)

Enfortumab Vedotin-induced Hyperglycemia and Ileal Conduit Reconstruction-induced Metabolic Acidosis
por: Sato, Takaaki, et al.
Publicado: (2023)

Review of Toxic Epidermal Necrolysis
por: Harris, Victoria, et al.
Publicado: (2016)

Toxic Epidermal Necrolysis and Sepsis
por: Alves, Daniela Dias, et al.
Publicado: (2016)

Vandetanib induced phototoxic reaction progressed to toxic epidermal necrolysis()
por: Gul, Busra Demirbag, et al.
Publicado: (2022)

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin
por: Jain, Rohit K, et al.
Publicado: (2020)

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma
por: Adib, Elio, et al.
Publicado: (2021)

The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis
por: Sarfaty, Michal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9vim3a7hm8i31j7ipdi0ug7hmh